Eslicarbazepine Acetate Monotherapy Long Term Study

This is a long term, multicenter, open-label, safety extension study in subjects with partial
onset seizures who have just completed, discontinued, or exited the 18-week treatment phase
of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option of
continuing study drug treatment post 1 year until a subject discontinues study, the study
drug becomes clinically available in the subject's locale, or the sponsor terminates the
study drug clinical development program.

This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired
by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to
Sunovion Pharmaceuticals Inc.

Subject Inclusion/Exclusion Criteria:

- Subject who completed, exited, or discontinued for reasons other than safety from the
18-week treatment phase of Protocols 093-045 or 093-046 and are willing to continue
participation in this study are eligible. Subject must have completed at least the
first 3 weeks of the 18-week double-blind treatment period of Protocols 093-045 or
093-046 to be eligible.

- Subject must give written informed consent prior to participation in the study. For
subjects <18 years of age, the informed consent must be signed by the subject's parent
or legal guardian, and, when appropriate and/or required by state or local law, minor
subjects must give written informed assent prior to participation in the study. All
subjects must sign privacy authorization form, if applicable. All females of child
bearing potential (≤65 years of age) must also sign the "Women of Childbearing
Potential" Addendum.

- Subjects must, in the opinion of the Investigator (with consultation with Medical
Monitor as appropriate), continue to potentially benefit from continued study
participation and have no new medical conditions that would preclude study
participation.

- If female subject, must continue the accepted method of birth control defined in
Protocols 093-045 or 093-046 for the duration of this study as well

- Criterion for Continuation into the Post 1 year Part of Study:

For subjects to continue into the post 1 year part of the study, subjects must, in the
opinion of the Investigator (with consultation with Medical Monitor, as appropriate),
continue to potentially benefit from continued study participation and have no new medical
conditions that would preclude study participation.